have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

Huge congrats to our research collaborators @KitePharma on their 2nd CAR T cell approval. Breakthrough for mantel cell lymphoma patients! We're incredibly fortunate to be working with them on next generation NK cell therapies

Kite, a Gilead Company@KitePharma

We are incredibly proud to announce the approval our second #CARTcell therapy and look forward to continuing our research for patients.

Here at @oNKo_innate, we envisage unique NK cell therapies at different stages of cancer. Our CSO @Dr_Nick_Bikes recently presented his view of the NK cell - Cancer Immunity Cycle. With @GileadSciences @KitePharma we are developing novel NK cell immunotherapies to #endcancer

Load More...
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
o o
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are